» Articles » PMID: 37046558

The Association of Circulating L-Carnitine, γ-Butyrobetaine and Trimethylamine N-Oxide Levels with Gastric Cancer

Abstract

Our study aimed to evaluate the association between gastric cancer (GC) and higher concentrations of the metabolites L-carnitine, γ-butyrobetaine (GBB) and gut microbiota-mediated trimethylamine N-oxide (TMAO) in the circulation. There is evidence suggesting that higher levels of TMAO and its precursors in blood can be indicative of either a higher risk of malignancy or indeed its presence; however, GC has not been studied in this regard until now. Our study included 83 controls without high-risk stomach lesions and 105 GC cases. Blood serum L-carnitine, GBB and TMAO levels were measured by ultra-high-performance liquid chromatography-mass spectrometry (UPLC/MS/MS). Although there were no significant differences between female control and GC groups, we found a significant difference in circulating levels of metabolites between the male control group and the male GC group, with median levels of L-carnitine reaching 30.22 (25.78-37.57) nmol/mL vs. 37.38 (32.73-42.61) nmol/mL ( < 0.001), GBB-0.79 (0.73-0.97) nmol/mL vs. 0.97 (0.78-1.16) nmol/mL ( < 0.05) and TMAO-2.49 (2.00-2.97) nmol/mL vs. 3.12 (2.08-5.83) nmol/mL ( < 0.05). Thus, our study demonstrated the association between higher blood levels of L-carnitine, GBB, TMAO and GC in males, but not in females. Furthermore, correlations of any two investigated metabolites were stronger in the GC groups of both genders in comparison to the control groups. Our findings reveal the potential role of L-carnitine, GBB and TMAO in GC and suggest metabolic differences between genders. In addition, the logistic regression analysis revealed that the only significant factor in terms of predicting whether the patient belonged to the control or to the GC group was the blood level of L-carnitine in males only. Hence, carnitine might be important as a biomarker or a risk factor for GC, especially in males.

Citing Articles

Metabolomic profiling of upper GI malignancies in blood and tissue: a systematic review and meta-analysis.

Balonov I, Mattis M, Jarmusch S, Koletzko B, Heinrich K, Neumann J J Cancer Res Clin Oncol. 2024; 150(7):331.

PMID: 38951269 PMC: 11217139. DOI: 10.1007/s00432-024-05857-5.


Distinguishing benign and malignant thyroid nodules using plasma trimethylamine N-oxide, carnitine, choline and betaine.

Shi L, Guo M, Shi C, Gao G, Xu X, Zhang C J Cancer Res Clin Oncol. 2024; 150(3):142.

PMID: 38503944 PMC: 10951046. DOI: 10.1007/s00432-024-05666-w.


Contributions of the Microbiome-Derived Metabolome for Risk Assessment and Prognostication of Pancreatic Cancer.

Leon-Letelier R, Dou R, Vykoukal J, Yip-Schneider M, Maitra A, Irajizad E Clin Chem. 2024; 70(1):102-115.

PMID: 38175578 PMC: 11836914. DOI: 10.1093/clinchem/hvad186.

References
1.
van der Laan T, Kloots T, Beekman M, Kindt A, Dubbelman A, Harms A . Fast LC-ESI-MS/MS analysis and influence of sampling conditions for gut metabolites in plasma and serum. Sci Rep. 2019; 9(1):12370. PMC: 6710273. DOI: 10.1038/s41598-019-48876-w. View

2.
Zhu H, Yang X, Zhang C, Zhu C, Tao G, Zhao L . Red and processed meat intake is associated with higher gastric cancer risk: a meta-analysis of epidemiological observational studies. PLoS One. 2013; 8(8):e70955. PMC: 3743884. DOI: 10.1371/journal.pone.0070955. View

3.
Bae S, Ulrich C, Neuhouser M, Malysheva O, Bailey L, Xiao L . Plasma choline metabolites and colorectal cancer risk in the Women's Health Initiative Observational Study. Cancer Res. 2014; 74(24):7442-52. PMC: 4268282. DOI: 10.1158/0008-5472.CAN-14-1835. View

4.
Wang M, Wang K, Liao X, Hu H, Chen L, Meng L . Carnitine Palmitoyltransferase System: A New Target for Anti-Inflammatory and Anticancer Therapy?. Front Pharmacol. 2021; 12:760581. PMC: 8576433. DOI: 10.3389/fphar.2021.760581. View

5.
Oellgaard J, Abitz Winther S, Hansen T, Rossing P, von Scholten B . Trimethylamine N-oxide (TMAO) as a New Potential Therapeutic Target for Insulin Resistance and Cancer. Curr Pharm Des. 2017; 23(25):3699-3712. DOI: 10.2174/1381612823666170622095324. View